ImageneBio (NASDAQ:IMA) and Agenus (NASDAQ:AGEN) Critical SurveyDefense World · Oct 6, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkGlobeNewsWire · Sep 8, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Aug 17, 2026
ImageneBio Reports Second Quarter 2026 Financial ResultsGlobeNewsWire · Aug 5, 2026ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.98 | -$0.63 | Beat |
| May 7, 2026 | -$0.70 | -$0.95 | Miss |
| Mar 5, 2026 | -$1.45 | -$0.62 | Beat |
| Nov 12, 2025 | -$1.47 | -$2.91 | Miss |
| Jul 24, 2025 | -$0.14 | -$0.06 | Beat |
| May 8, 2025 | -$0.21 | -$0.18 | Beat |